688076 ST诺泰生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)7.07811.78416.7568.0456.976
总资产报酬率 ROA (%)3.1155.6279.3815.3965.563
投入资产回报率 ROIC (%)3.4926.28210.3075.9116.031

边际利润分析
销售毛利率 (%)59.49662.64467.68560.97057.573
营业利润率 (%)25.78621.03327.58618.35118.978
息税前利润/营业总收入 (%)25.50621.53128.12317.87218.693
净利润/营业总收入 (%)18.39616.74924.60716.00818.687

收益指标分析
经营活动净收益/利润总额(%)148.800128.491112.187119.14384.864
价值变动净收益/利润总额(%)3.3260.976-0.3931.82614.765
营业外收支净额/利润总额(%)-23.007-13.356-2.215-9.553-1.389

偿债能力分析
流动比率 (X)1.1371.1611.1441.5361.909
速动比率 (X)0.7280.7640.8111.1481.322
资产负债率 (%)56.11655.46647.21438.32423.931
带息债务/全部投入资本 (%)45.22945.78038.08529.95515.346
股东权益/带息债务 (%)107.715109.180151.307223.701538.466
股东权益/负债合计 (%)77.92779.858110.885159.534315.406
利息保障倍数 (X)5.6147.23524.77815.938-744.597

营运能力分析
应收账款周转天数 (天)88.16995.64991.71594.33499.796
存货周转天数 (天)351.736358.030329.524312.642374.107